CG
BIS icon

Cutler Group’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Cutler Group’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,250
Closed -$12K – 6350
2017
Q1 		$12K Buy
+1,250
New +$295K ﹤0.01% 3839
2016
Q3 		– Sell
-1,675
Closed -$5K – 6654
2016
Q2 		$5K Sell
1,675
-4,363
-72% -$1.38M ﹤0.01% 4882
2016
Q1 		$184K Buy
6,038
+5,725
+1,829% +$1.99M 0.01% 1070
2015
Q4 		$3K Buy
+313
New +$80.5K ﹤0.01% 5227

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Cutler Group's BIS Position: Q2 2021 in Review

Cutler Group sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2021, closing a stake of 50 shares — an estimated $2K sold.

Cutler Group first reported a position in BIS in Q1 2016 and held it in 6 quarters. The position peaked at $80K in Q2 2016. 7 funds tracked by Wall St. Rank hold BIS as of Q2 2021.

  • Cutler Group reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 50 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2021, an estimated $2K.
  • Cutler Group first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2016 and held it in 6 quarters.
  • Cutler Group's ProShares UltraShort NASDAQ Biotechnology position peaked at $80K in Q2 2016.
  • 7 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.